Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

NCT00853047 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoid Syndrome

Interventions

DRUG: Telotristat etiprate
DRUG: Octreotide LAR Depot
DRUG: Placebo

Sponsor

Lexicon Pharmaceuticals